Drug Trial Radar · NCT07297979
Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Apr 8, 2026
Primary completion
May 26, 2030
Study completion May 26, 2030
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Dec 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objectives of this trial are to determine the recommended dose for expansion of xaluritamig (dose confirmation part only) and to determine the safety and tolerability of xaluritamig in adult, adolescent and pediatric participants with relapsed or refractory EWS.
Conditions
- Ewing Sarcoma
Interventions
XaluritamigDrug
Participants will receive xaluritamig via short-term intravenous (IV) infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing a Dose-limiting Toxicity (DLT) (Part 1 Only)Time frame: Up to 42 days
- Number of Participants with Treatment-emergent Adverse EventsTime frame: Up to approximately 2.5 years
Locations
13 sites in 2 countries. Site status is shown where the registry gives one.
Cedars Sinai Medical Center
Los Angeles, California · Recruiting
University of California Los Angeles
Los Angeles, California · Recruiting
Johns Hopkins University
Baltimore, Maryland · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
C.S. Mott Children's Hospital
Ann Arbor, Michigan · Recruiting
Mayo Clinic Childrens Center
Rochester, Minnesota · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Childrens Hospital of Philadelphia
Philadelphia, Pennsylvania · Recruiting
University of Pittsburgh Medical Center Childrens Hospital of Pittsburgh
Pittsburgh, Pennsylvania · Recruiting
University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Chris OBrien Lifehouse
Camperdown, New South Wales, Australia · Recruiting
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia · Recruiting
Perth Childrens Hospital
Nedlands, Western Australia, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.